DiaMedica Therapeutics Inc. (DMAC) Stock Price & Analysis
DiaMedica Therapeutics Inc. (DMAC) closed at USD 8.63 on Thursday, October 22, 2026, down 0.69% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 8.69; the Oct 22, 2026 session ranged USD 8.51–8.95 on volume of 87,987 shares. Market capitalization is $465.38M, with a 52-week range of USD 5.25–10.42 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DMAC.md
Key facts (DMAC)
- 1 of 80 tracked superinvestors hold DMAC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 15.5 (range 11–25).
- Total return with dividends: 1Y +27.7% vs S&P 500 +14.9%; 5Y +114.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.21, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DMAC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M | -$39.2M |
| Net income | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M | -$37.5M |
| EPS (diluted) | -$0.65 | — | — | — | — | — |
| Free cash flow | -$12.3M | -$11.6M | -$18.8M | -$22.1M | -$29.1M | -$31.5M |
| Cash + short-term investments | $45.1M | $33.5M | $52.9M | $44.1M | $59.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DMAC)
P/B 12.1x · FCF yield -6.78% · Earnings yield -8.07%
Superinvestors (SEC 13F-HR, Q2 2026) (DMAC)
1 of 80 tracked investors hold DMAC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Leon Cooperman | Omega Family Office | 0.68% | $24.3M | Added +70.8% |
Analysts (DMAC)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 15.5 (low 11, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | HC Wainwright & Co. | Reiterated | Buy | $12 |
Total return (dividends reinvested) (DMAC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +27.7% | +114.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +27.8% | +16.5% |
| Volatility (annualized) | 57.1% | 71.2% |
| Max drawdown | -43.2% (Dec 2025→Jun 2026) | -75.7% (Nov 2021→Nov 2022) |
DMAC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.21 | $-0.21 | -2.4% | $0 | 4 |
| Next quarter (ends Dec 2026) | $-0.22 | $-0.23 | -1.1% | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-0.81 | $-0.83 | -2.1% | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-0.75 | $-0.88 | -15.1% | $0 | 4 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 8.63 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 8.69 |
| Open | USD 8.63 |
| Day Range | USD 8.51 – 8.95 |
| 52-Week Range | USD 5.25 – 10.42 |
| Volume | 87,987 shares |
| Market Cap | $465.38M |
| Exchange | NCM |
Technical Analysis (DMAC)
Nexqual's technical model rates DMAC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.77 (neutral) |
| vs SMA50 | Above (USD 7.31) |
| MACD | 0.29 (positive) |
Analyst Ratings (DMAC)
Wall Street analysts rate DMAC "Buy" based on 5 analysts, with a mean price target of USD 15.5 (range USD 11–25), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 15.5 |
| High Target | USD 25 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (DMAC)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.19 vs est -0.2 ▲ beat |
| 2026-03-31 | USD -0.19 vs est -0.19 ▼ miss |
| 2025-12-31 | USD -0.17 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.17 vs est -0.16 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (DMAC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -114.61% |
| Debt / Equity | 0 |
| Current Ratio | 6.72 |
| Total Cash | $43.50M |
| Total Debt | $185,000 |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (DMAC)
Nexqual rates DiaMedica Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $44M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$29M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -115%, ROA -64.1% |
Ownership (DMAC)
| Insider Ownership | +27.83% |
|---|---|
| Institutional Ownership | +40.92% |
| Shares Outstanding | 53.93M |
| Float | 25.30M |
| Short % of Float | +15.42% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (DMAC)
DiaMedica Therapeutics Inc. is led by Dietrich John Pauls, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President, CEO & Director | Dietrich John Pauls |
|---|---|
| CFO & Corporate Secretary | Scott Kellen |
| Chief Technology Officer | Ambarish Shah |
Major Backers & Investors (DMAC)
Notable institutional backers of DiaMedica Therapeutics Inc. include Cooperman, Leon G., Paragon Associates & Paragon Associates Ii Joint Venture, Millennium Management, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cooperman, Leon G. | 6.4% |
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.62% |
| Millennium Management | 1.57% |
| Fidelity | 1.14% |
| Bleichroeder LP | 0.71% |
| Osaic Holdings Inc. | 0.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.18% |
| Geode Capital | 1.66% |
| State Street | 1.2% |
| Vanguard Group | 0.66% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt